Introduction: Type 2 diabetes mellitus (T2DM) is linked to increased vascular morbidity and mortality. Well-controlled diabetes is indicated by effective glycemic and HbA1c regulation and low-grade inflammation management. This study evaluates glycolipid control and inflammatory status in T2DM patients on metformin.

Methods: A pilot study involved 11 participants divided into two groups: a T2DM group on metformin therapy and a control, non-diabetic group. Demographic, clinical, anthropometric, glycolipid (glycemia, HbA1c, TC, LDL-C, HDL-C, TG), and inflammatory parameters (CRP, FFA, PL, UA, FLI) were evaluated.

Results: Significant intergroup differences were found in glycemia, HbA1c, TC, LDL-C, UA, FLI, and WC. Glycemia influenced PL (p<0.05), UA (p<0.01), and FLI (p<0.01), while HbA1c affected UA (p<0.05) and FLI (p<0.01). LDL-C and HDL-C impacted UA (p<0.05, p<0.01). Age affected FLI (p<0.05), gender influenced PL (p<0.01), and BW, BH, WC, and BMI significantly impacted UA and FLI (p<0.01).

Conclusion: T2DM patients showed signs of low-grade systemic inflammation, emphasizing the need for comprehensive diabetes management and early cardiovascular risk detection. Intensified interventions are necessary for patients with inadequate glycemic control on metformin.